

**Freedom of Information Request**

**Ref: UHB 20-111**

6 March 2020

By Email

Dear Sir/Madam

Thank you for your request for information under the Freedom of Information Act 2000. The Trust's response is as follows:

Please note, patients on trials have not been included (as often drug vs placebo) and the time period covered is 1st Sept 19 – 29th Feb 2020.

1. How many patients with cutaneous squamous cell carcinoma have you treated [eg surgery, chemotherapy or radiotherapy] in the past 3 months?  
3 with cemiplimab.  
Total Radical and Palliative Skin SCC (C44) Radiotherapy: 25 patients. Period covered Nov 19 - Jan 2020).
2. How many adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma have you treated [eg surgery, chemotherapy or radiotherapy] in the past 3 months?  
3 with cemiplimab.  
Palliative Skin SCC Radiotherapy: 7
3. Of these how many are not candidates for curative surgery or curative radiation?  
18
4. In the past 3 months, how many adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation have you treated with the following;
  - a. Libtayo (cemiplimab) – 3
  - b. Non curative surgery only
  - c. Non curative surgery + chemotherapy\* - zero patients received chemotherapy as defined below
  - d. Non curative surgery + radiotherapy
  - e. Non curative surgery + chemotherapy\* + radiotherapy - zero patients received chemotherapy as defined below
  - f. Chemotherapy\* only - zero patients received chemotherapy as defined below
  - g. Chemotherapy\* + radiotherapy - zero patients received chemotherapy as defined below

- h. Non curative radiotherapy only
- i. No treatment
- j. Palliative Care / Best Supportive care
- k. Other [please state]

\*chemotherapy such as cisplatin, doxorubicin, 5-fluorouracil (5-FU), capecitabine, topotecan, or etoposide.

5. Does your trust treat adult multiple myeloma [MM]? - if you refer your multiple myeloma patients to another centre, please state which.  
Radiotherapy do treat MM (C90)
6. If yes, then how many multiple myeloma patients, have been treated in the past 6 months with the following;
- a. Bortezomib [Velcade] – 30
  - b. Carfilzomib [Kyprolis] – 0
  - c. Ixazomib [Ninlaro] – 3
  - d. Lenalidomide [Revlimid] – 17
  - e. Daratumumab [Darzalex] – 17
  - f. Melphalan, prednisolone and thalidomide (known as MPT) – 1
  - g. Cyclophosphamide, thalidomide and dexamethasone (known as CTD) – 1
  - h. Pomalidomide [Imnovid] - 5
7. Over the past 6 months [latest possible], how many chronic lymphocytic leukaemia (CLL) patients have you treated?  
If possible how many CLL patients treated were new to therapy in the past 3 months?  
Radiotherapy CLL: Zero treated with Radiotherapy.
8. How many chronic lymphocytic leukaemia patients, have been treated in the past 6 months with the following;
- a. Fludarabine (Fludara), cyclophosphamide (Cytosan), and rituximab (known as FCR) – 1
  - b. Bendamustine and rituximab (known as BR) – 0
  - c. Ibrutinib [Imbruvica] – 17
  - d. Chlorambucil – 5
  - e. Obinutuzumab – 2
  - f. Idelalisib – 0
  - g. Fludarabine and rituximab (known as FR) – 0
  - h. High-dose prednisone and rituximab – 0
  - i. Pentostatin (Nipent), cyclophosphamide, and rituximab (known as PCR) – 0
  - j. Alemtuzumab (Campath) with rituximab – 0

This concludes our response. We trust that you find this helpful, but please do not hesitate to contact us directly if we can be of any further assistance.

If, after that, you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Director of Corporate Governance  
University Hospitals Bristol NHS Foundation Trust  
Trust Headquarters  
Marlborough Street  
Bristol  
BS1 3NU

Please remember to quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

#### Publication

Please note that this letter and the information included/attached will be published on our website as part of the Trust's Freedom of Information Publication Log. This is because information disclosed in accordance with the Freedom of Information Act is disclosed to the public, not just to the individual making the request. We will remove any personal information (such as your name, email and so on) from any information we make public to protect your personal information.

To view the Freedom of Information Act in full please click [here](#).

Yours sincerely

**FOI Team**  
**UH Bristol NHS Foundation Trust**